Navigation Links
Comparison of Biopharmaceutical Industry Between China and India 2013
Date:4/18/2013

DUBLIN, April 18, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Comparison of Biopharmaceutical Industry between China and India 2013" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The report, Comparison of Biopharmaceutical Industry between China and India, has revealed the relative competencies of the biopharmaceutical industry in these two countries, including their current capabilities and capacities in biologic drug R&D and manufacturing.

It is the first time in the history that the biopharmaceutical industries in both China and India are completely analyzed and compared. The report thus presents a complete picture to multinational companies of which country can do what at present and which one between China and India is better in which areas and thus best suitable for what types of collaboration, etc. Moreover, it provides clear insights of the future development directions of the biopharmaceutical industry in each of these two countries.

The report is thus a must-read book to all global pharmaceutical, biopharmaceutical and financial investment companies that are interested to have a best position in either one of these two countries. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of biopharmaceutical industry in their own countries.

Key Features of the Report

- The report is designed to help professionals in the global biopharmaceutical industry better understand the current development states, technical capabilities and relative competencies of China and India in biologic drug R&D and manufacturing, as well as the future growth potentials of their biopharmaceutical industries.

- The report thus first analyzed and compared both in detail and in depth the current states of the biopharmaceutical industry in both China and India. It is the first time that the report revealed the similarities and differences between China and India in biopharmaceutical industry, their strengths and weaknesses in this industry, and the advantages and disadvantages each country possesses for future development of this nascent but dynamically growing industry.

- The report also analyzed and compared the current structural compositions of the biopharmaceutical industry in China and India, and the biopharmaceutical product scope and type each country is currently able to produce. It thus revealed the current manufacturing capabilities and capacities of the Chinese and Indian biopharmaceutical industries.

- Meanwhile, the report also analyzed and compared the novel biologic drugs and biosimilar products currently under development in those major biopharma companies in each country. It thus revealed the current capabilities of Chinese and Indian biopharma companies in biologic drug R&D.

- More importantly, the report also analyzed the opportunities and challenges in the foreseeable future facing Chinese and Indian biopharma companies in the competitive global biopharmaceutical market, as well as the actions and strategies each country is currently taking to enhance their competitiveness.

- The in-depth analysis and in-detail comparison the report has conducted have provided a clear and complete picture of the current relative competiveness of China and India in the global biopharmaceutical industry. It thus greatly helps global pharmaceutical and biopharmaceutical companies to best gauge the possible collaboration and partnership opportunities with local counterparts in these two countries.

- The report also analyzed in detail the current market sizes, past growth histories and the future growth potentials of the biopharmaceutical market in each country, including the submarket sectors of therapeutic proteins, vaccines and therapeutic mAbs. It has thus revealed both the attractiveness of the local biopharmaceutical markets and their differences. The report will thus greatly facilitate the global pharmaceutical and biopharmaceutical companies to formulate their best market strategies in these two important yet still dynamically growing markets.

Key Topics Covered:

Executive Summary

  • Attractions of fast growing Chinese and Indian biopharmaceutical markets
  • Comparison of biopharmaceutical manufacturing between China and India
  • Comparison of biopharmaceutical R&D between China and India
  • Outlook of future growth potentials of biopharmaceutical industry in China and India

Chapter One - Attractions of Fast Growing Chinese and Indian Biopharmaceutical Markets

Chapter Two - Comparison of Biopharmaceutical Manufacturing between China and India

Chapter Three - Comparison of Biopharmaceutical R&D between China and India

Chapter Four - Outlook of Future Growth Potentials of Biopharmaceutical Industry in China and India

Index I. Chinese Companies Cited in the Report

Index II. Indian Companies Cited in the Report


For more information visit Comparison of Biopharmaceutical Industry between China and India 2013

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
2. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
6. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
7. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
8. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
9. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
11. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... quarter and full year ended December 31, 2015. ... a transformational year for Vanda with the continued growth ... approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, ... to our U.S. product portfolio builds on this success ...
(Date:2/10/2016)... --> --> This press release is intended for ... Japan .  --> A separate press release has been prepared ... Shire continues to strengthen its presence in ... continues to strengthen its presence in Japan ... continues to strengthen its presence in Japan ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited to ... water brand owners that topped the list as a result of their commitment to ... premier brand was Tibet 5100, a top notch water company that specializes in providing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience ... across their network of laboratory service centers across the country. Launched in April of ... in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):